Opinion|Videos|May 16, 2025
Long-Acting HIV Therapies: Real-World Data and Clinical Application
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how the injectable combination of cabotegravir and rilpivirine performed well in the real-world OPERA cohort, with over 95% of patients maintaining virologic suppression. However, adherence to injection schedules remains a challenge, with only 62% receiving injections on time.
Advertisement
Long-Acting Injectable Therapy – Real-World Evidence
Key Themes:
- Injectable Option: Cabotegravir (integrase inhibitor) plus rilpivirine as an intramuscular injection given every other month
- Real-World Performance: The OPERA cohort followed nearly 3000 US patients receiving this combination outside clinical trials.
- Adherence Challenges: Importance of timely injections, with 62% of patients receiving injections on schedule and 12% missing injections
- Clinical Implications: Risk of resistance development if injections are delayed or missed
Notable Insights from Dr Sharon Walmsley:
- Real-world virologic suppression rates exceeded 95%, with less than 1% experiencing virologic failure, mirroring clinical trial results.
- High body mass index was not associated with treatment failure in this cohort, contrasting with some earlier studies, likely due to improved administration techniques (longer needles).
- Injectable therapy offers psychological benefits to patients who are “tired of swallowing pills” or find daily oral medication a constant reminder of HIV status.
- Clinics need systematic approaches to track and ensure timely administration of injections to prevent resistance development.
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5